Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Thomas J Ruth

Showing results (51-60 of 55) with videos related to

Pageof 6
Sort By:
You have reached the last page of results.This site can display upto 55 results.
Annals of Neurology|January 20, 2011
Age-specific progression of nigrostriatal dysfunction in Parkinson's diseaseRaúl de la Fuente-Fernández, Michael Schulzer, Lisa Kuramoto, et al.
Cancer Research|August 24, 2010
Novel matrix metalloproteinase inhibitor [18F]marimastat-aryltrifluoroborate as a probe for in vivo positron emission tomography imaging in cancerUlrich auf dem Keller, Caroline L Bellac, Ying Li, et al.
Brain : a Journal of Neurology|August 6, 2005
PET in LRRK2 mutations: comparison to sporadic Parkinson's disease and evidence for presymptomatic compensationJohn R Adams, Hinke van Netten, Michael Schulzer, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 18, 2008
Irinophore C, a novel nanoformulation of irinotecan, alters tumor vascular function and enhances the distribution of 5-fluorouracil and doxorubicinJennifer H E Baker, Jeffrey Lam, Alaistair H Kyle, et al.
The Lancet. Neurology|February 20, 2018
The effect of LRRK2 mutations on the cholinergic system in manifest and premanifest stages of Parkinson's disease: a cross-sectional PET studyShu-Ying Liu, Daryl J Wile, Jessie Fanglu Fu, et al.
Pageof 6

Showing results (51-60 of 55) with videos related to

Sort By:
Pageof 6
You have reached the last page of results.This site can display upto 55 results.
Annals of Neurology|January 20, 2011
Age-specific progression of nigrostriatal dysfunction in Parkinson's diseaseRaúl de la Fuente-Fernández, Michael Schulzer, Lisa Kuramoto, et al.
Cancer Research|August 24, 2010
Novel matrix metalloproteinase inhibitor [18F]marimastat-aryltrifluoroborate as a probe for in vivo positron emission tomography imaging in cancerUlrich auf dem Keller, Caroline L Bellac, Ying Li, et al.
Brain : a Journal of Neurology|August 6, 2005
PET in LRRK2 mutations: comparison to sporadic Parkinson's disease and evidence for presymptomatic compensationJohn R Adams, Hinke van Netten, Michael Schulzer, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 18, 2008
Irinophore C, a novel nanoformulation of irinotecan, alters tumor vascular function and enhances the distribution of 5-fluorouracil and doxorubicinJennifer H E Baker, Jeffrey Lam, Alaistair H Kyle, et al.
The Lancet. Neurology|February 20, 2018
The effect of LRRK2 mutations on the cholinergic system in manifest and premanifest stages of Parkinson's disease: a cross-sectional PET studyShu-Ying Liu, Daryl J Wile, Jessie Fanglu Fu, et al.
Pageof 6